In a report released yesterday, Vamil Divan from Credit Suisse maintained a Buy rating on Aimmune Therapeutics (AIMT), with a price target of $40. The company’s shares closed yesterday at $23.73, close to its 52-week low of $21.38.
According to TipRanks.com, Divan has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.6% and a 40.5% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Merck & Company, and Portola Pharma.
Aimmune Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $55.50.
See today’s analyst top recommended stocks >>
Based on Aimmune Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $51.7 million. In comparison, last year the company had a GAAP net loss of $41.17 million.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
